Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Harvard Business School
QuintilesIMS
Covington
Boehringer Ingelheim
Teva

Generated: August 23, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR VYXEOS

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Clinical Trials for VYXEOS

Trial ID Title Status Sponsor Phase Summary
NCT02533115 EAP of CPX-351 (VYXEOS) for Patients 60-75 Years of Age With Secondary AML Available Celator Pharmaceuticals N/A This study is a Phase IV Expanded Access Protocol (EAP) of CPX-351 in patients with secondary acute myeloid leukemia who are suitable for treatment with intensive chemotherapy.
NCT03555955 A Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX-351 Not yet recruiting Jazz Pharmaceuticals Phase 1 This study evaluates the pharmacokinetics and safety of CPX-351 in patients with moderate or severe renal impairment.
NCT03572764 CPX-351 (Vyxeos™) for Transplant Eligible, Higher Risk Patients With Myelodysplastic Syndrome Not yet recruiting Jazz Pharmaceuticals Phase 1 This is a pilot and feasibility study of transplant eligible, higher risk myelodysplastic syndrome (MDS) patients to determine the safety and tolerability of a lower -dose and higher-dose CPX-351 regimen, with secondary objectives including complete remission (CR) rates and proportion of patients proceeding to transplant.
NCT03572764 CPX-351 (Vyxeos™) for Transplant Eligible, Higher Risk Patients With Myelodysplastic Syndrome Not yet recruiting Washington University School of Medicine Phase 1 This is a pilot and feasibility study of transplant eligible, higher risk myelodysplastic syndrome (MDS) patients to determine the safety and tolerability of a lower -dose and higher-dose CPX-351 regimen, with secondary objectives including complete remission (CR) rates and proportion of patients proceeding to transplant.
NCT03575325 Vyxeos(CPX-351) in Adults w R/R Acute Lymphoblastic Leukemia Recruiting Jazz Pharmaceuticals Phase 2 This study involves Vyxeos (CPX-351), a formulation of a fixed combination of the two anti-tumor drugs, cytarabine and daunorubicin that will be given as an infusion over 90 minutes. This study will use what is called a "liposome" injection. This is a special fat capsule (called a liposome) that surrounds the cytarabine and daunorubicin and protects the drugs from being eliminated/destroyed by the body.
NCT03575325 Vyxeos(CPX-351) in Adults w R/R Acute Lymphoblastic Leukemia Recruiting H. Lee Moffitt Cancer Center and Research Institute Phase 2 This study involves Vyxeos (CPX-351), a formulation of a fixed combination of the two anti-tumor drugs, cytarabine and daunorubicin that will be given as an infusion over 90 minutes. This study will use what is called a "liposome" injection. This is a special fat capsule (called a liposome) that surrounds the cytarabine and daunorubicin and protects the drugs from being eliminated/destroyed by the body.
>Trial ID >Title >Status >Phase >Summary

Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for VYXEOS

Condition Name

Condition Name for VYXEOS
Intervention Trials
Recurrent Acute Myeloid Leukemia 4
Acute Myeloid Leukemia 3
Refractory Acute Myeloid Leukemia 2
Acute Lymphoblastic Leukemia 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for VYXEOS
Intervention Trials
Leukemia 11
Leukemia, Myeloid, Acute 8
Leukemia, Myeloid 7
Preleukemia 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for VYXEOS

Trials by Country

Trials by Country for VYXEOS
Location Trials
United States 17
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for VYXEOS
Location Trials
Texas 3
California 3
Florida 2
New York 2
Ohio 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for VYXEOS

Clinical Trial Phase

Clinical Trial Phase for VYXEOS
Clinical Trial Phase Trials
Phase 2 4
Phase 1/Phase 2 1
Phase 1 6
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for VYXEOS
Clinical Trial Phase Trials
Not yet recruiting 9
Recruiting 3
Available 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for VYXEOS

Sponsor Name

Sponsor Name for VYXEOS
Sponsor Trials
National Cancer Institute (NCI) 5
Jazz Pharmaceuticals 4
M.D. Anderson Cancer Center 3
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for VYXEOS
Sponsor Trials
Other 10
Industry 7
NIH 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Moodys
Chubb
Merck
McKesson
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.